Pan-CD44 monoclonal antibodies have been shown to reduce tumor growth, metastasis and post-radiation recurrence of pancreatic xenograft tumors [85], while have also been reported to drastically decrease the leukemic population in mice transplanted with human acute myeloid leukemic stem cells, as well [86]. This evidence concerns the gene CD44 and neoplasm.